Neurocrine Biosciences (NBIX) Non-Current Deffered Revenue (2010 - 2018)

Neurocrine Biosciences has reported Non-Current Deffered Revenue for 9 years, with the latest figure at $18.1 million in Q4 2018.

• For the quarter ending Q4 2018, Non-Current Deffered Revenue rose 77.05% year-over-year to $18.1 million; the trailing twelve-month figure through Dec 2018 stood at $18.1 million (up 77.05% YoY), and the FY2018 full-year result was $18.1 million, up 77.05% from the prior year.
• Non-Current Deffered Revenue for Q4 2018 stood at $18.1 million, up from $12.1 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $18.1 million in Q4 2018, with the low at $1.6 million in Q3 2016.
• Historically, Non-Current Deffered Revenue has averaged $7.6 million across 5 years, with a median of $10.2 million in 2015.
• Annual changes were most pronounced in 2016 — Non-Current Deffered Revenue slumped 84.46% — and 2017, when it surged 543.46%.
• Neurocrine Biosciences' Non-Current Deffered Revenue stood at $1.9 million in 2014, then jumped by 445.07% to $10.2 million in 2015, then changed by 0.0% to $10.2 million in 2016, then changed by 0.0% to $10.2 million in 2017, then soared by 77.05% to $18.1 million in 2018.
• The last three Non-Current Deffered Revenue figures came in at $18.1 million (Q4 2018), $12.1 million (Q3 2018), and $5.3 million (Q2 2018), per Business Quant data.